Impact of tanezumab on health status, non-work activities and work productivity in adults with moderate-to-severe osteoarthritis

BACKGROUND: To evaluate the impact of tanezumab on health status, non-work activities, and work productivity in a pooled analysis of two large phase 3 osteoarthritis (OA) studies. METHODS: Subcutaneous tanezumab (2.5 mg and 5 mg) was tested in double-blind, placebo-controlled, 16-week (NCT02697773)...

Descripción completa

Detalles Bibliográficos
Autores principales: Conaghan, Philip G., Abraham, Lucy, Viktrup, Lars, Cislo, Paul
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2022
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8809015/
https://www.ncbi.nlm.nih.gov/pubmed/35105318
http://dx.doi.org/10.1186/s12891-022-05029-x

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8809015/
https://www.ncbi.nlm.nih.gov/pubmed/35105318
http://dx.doi.org/10.1186/s12891-022-05029-x

Ejemplares similares